Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

153.70 -1.28 (-0.82%)
Streaming Delayed Price Updated: 11:47 AM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
71 72 Next >
News headline image
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗
 
Via Benzinga
News headline image
Salesforce Earnings Top Views. Software Stock Falls On Weak Revenue Outlook. ↗
Salesforce stock fell after the company's revenue guidance for fiscal 2026 came in below expectations, despite the ramp of new AI products. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
Gilead Sciences Unusual Options Activity ↗
 
Via Benzinga
News headline image
European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
News headline image
What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know. 
Via StockStory
News headline image
How Is The Market Feeling About Gilead Sciences? ↗
 
Via Benzinga
News headline image
16 Analysts Have This To Say About Gilead Sciences ↗
 
Via Benzinga
News headline image
Why Gilead Sciences Stock Is Jumping Today ↗
Via The Motley Fool
News headline image
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
Gilead Pharmaceuticals is back to highs not seen in a decade as its HIV treatment franchise surges and awaits its 100% effective HIV prevention drug in summer 
Via MarketBeat
Topics Death
News headline image
Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board? ↗
JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management. 
Via Stocktwits
News headline image
Large Cap Biopharmaceutical Metrics And Performance Q1 2025 ↗
Tariffs could have big impact on earnings in 2025. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Gilead’s Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
From Gilead Sciences, Inc.
Via Business Wire
News headline image
This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results tomorrow afternoon. Here’s what you need to know. 
Via StockStory
News headline image
Bullish Setups ↗
You know things are bad when I stoop to offering some bullish setups, but that’s just where we’re at right now. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Robinhood, Gilead Sciences, Crocs, Lincoln Electric, HubSpot, GE HealthCare And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Moderna (MRNA) Q4 Earnings Report Preview: What To Look For
Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market open. Here’s what to expect. 
Via StockStory
News headline image
Top S&P500 movers in Wednesday's session ↗
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
News headline image
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention ↗
Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025. 
Via Benzinga
News headline image
These S&P500 stocks have an unusual volume in today's session ↗
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below. 
Via Chartmill
News headline image
Why Gilead Sciences (GILD) Stock Is Trading Up Today
Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the company reported impressive fourth-quarter results that exceeded analysts' revenue, EPS,... 
Via StockStory
News headline image
These S&P500 stocks are moving in today's session ↗
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
News headline image
Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday? ↗
A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New... 
Via Benzinga
Topics Economy
News headline image
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Discover the top S&P500 movers in Wednesday's pre-market session. ↗
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Gilead Wins Price-Target Boosts After Solid Q4, Retail Brushes Off Medicare Reform Hit To HIV Drugs ↗
Investors seem encouraged by the company's strong performance in its core business areas and the promise of further growth driven by its expanding pipeline. 
Via Stocktwits
News headline image
Markets Mixed On Powell Testimony, Q4 Earnings ↗
Market indexes were mixed today, after seeing all the majors in the red before the opening bell. The Dow closed up +123 points, +0.28%, while the S&P 500 squeaked by +2 points. 
Via Talk Markets
Topics Stocks Stocks / Equities
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.